82 results about "Normal lung" patented technology

The present invention identifies and quantifies changes in gene expression associated with non-small cell lung cancer NSCLC by examining gene expression in tissue from normal lung and diseased lung. The present invention also identifies and quantifies expression profiles which serve as useful diagnostic markers as well as markers that are useful to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism.

A system and computation method is disclosed that identifies radiation-induced lung injury after radiation therapy using 4D computed tomography (CT) scans. After deformable image registration, the method segments lung fields, extracts functional and textural features, and classifies lung tissues. The deformable registration locally aligns consecutive phases of the respiratory cycle using gradient descent minimization of the conventional dissimilarity metric. Then an adaptive shape prior, a first-order intensity model, and a second-order lung tissues homogeneity descriptor are integrated to segment the lung fields. In addition to common lung functionality features, such as ventilation and elasticity, specific regional textural features are estimated by modeling the segmented images as samples of a novel 7th-order contrast-offset-invariant Markov-Gibbs random field (MGRF). Finally, a tissue classifier is applied to distinguish between the injured and normal lung tissues.

The invention discloses polypeptide for specifically targeting a lung cancer cell and an application thereof. The polypeptide for specifically targeting the lung cancer cell has an amino acid sequence shown as SEQ ID NO.1, and is prepared by screening on the surface of the human lung cancer cell by an ex-vivo bacterial random polypeptide library exhibiting method and a flow cell sorting method. The polypeptide for specifically targeting the lung cancer cell can be applied to preparation of lung cancer diagnosing tracer, lung cancer cell detecting reagent and the like. The polypeptide for specifically targeting the lung cancer cell can be combined with a lung cancer A549 cell specifically, is not combined with a normal lung cell and other tumor cells; and the preparation method is simple, feasible and applicable to large-scale industrial production. The polypeptide for specifically targeting the lung cancer cell provides important theoretical and practical basis for early diagnosis, targeting therapy of the lung cancer and the like, and has a wide application prospect.

Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and / or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level.

Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and / or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level.

The invention discloses an HoxC11 gene or HoxC11 gene which can be used for preparing a lung adenocarcinoma pre-diagnostic reagent and a kit and preparing lung adenocarcinoma pre-diagnostic prognosis evaluation reagents or treatment drugs. Reverse transcription is performed after RNA is extracted from a normal lung tissue sample of lung adenocarcinoma, expression of HoxC11 is detected through a real-time fluorescence quantification method, and a result shows that HoxC11 can be highly expressed in lung adenocarcinoma tissue. It is promoted that HoxC11 can be used as a lung adenocarcinoma pre-diagnostic molecular marker. The powerful molecular biology tool is provided for lung adenocarcinoma auxiliary diagnosis and prognosis prediction, and the profound clinic significance and significant application and popularization prospects are achieved.

The invention discloses an application of a Lnc03729 gene c as a biomarker in the preparation of markers for diagnosis, prognosis evaluation and therapeutic guidance of lung adenocarcinoma. RNA is extracted from lung adenocarcinoma and normal lung tissue samples and is reversely transcribed, the expression of Lnc03729 is detected through a real-time fluorescent quantitative PCR technology, the expression of human lung adenocarcinoma cell Lnc03729 is exogenously up-regulated, and the change of the proliferation and the metastasis of the cells is detected through MTS and Transwell experiments. Aresult shows that the Lnc03729 is under-expressed in the lung adenocarcinoma tissues, and the up-regulation of the expression of the human lung adenocarcinoma cells Lnc03729 significantly down-regulates the proliferation and metastasis ability of the cells, so it is prompted that the Lnc03729 can be used as a marker for the malignancy and the patient prognosis evaluation of the lung adenocarcinoma cells. The application provides a powerful molecular biology tool for the auxiliary diagnosis, prognosis prediction and therapeutic guidance of the lung adenocarcinoma, and has far-reaching clinicalsignificance and important promotion and application prospects.

Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH / 3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers.

The invention discloses a whole genome screening method for screening relative BPDE oncogenes and comprises the steps that: (1) genome DNA is extracted from normal lung tissue; (2) AFLP DNA fragment is prepared; (3) immunomagnetic of AFLP DNA fragment interacting with BPDE is enriched and separated; (4) AFLP PCR is increased; (5) denatured polyacrylamide gel electrophoresis and silver stain visualization are done to selective PCR amplification products of AFLP; (6) differential fragment is recycled, amplified, cloned and tested for sequence and homologous similarity and analysis are done. The whole genome screening method for screening relative BPDE oncogenes of the invention is the high effective and specific method and more BPDE susceptible oncogenes are screened in the whole genome level, which provides a basis for stating BPDE carcinogenic molecular mechanism.

The invention relates to the field of biotechnologies, and in particular relates to a group of LncRNA biological markers for diagnosing human lung squamous carcinoma, a related kit and applications thereof. The group of LncRNA biological markers for diagnosing the human lung squamous carcinoma, provided by the invention, comprises ENST00000453324, ENST00000441841, uc011cly.2, NR_028500 and NR_046326. The LncRNA biological markers for diagnosing the human lung squamous carcinoma can be used for distinguishing human early lung squamous carcinoma, the AUC value of the LncRNA biological markers for distinguishing the early lung squamous carcinoma and pairing normal lung tissues can reach 0.932, and the sensitivity and the specificity can be 92% and 87% respectively.

The invention discloses application of a compound to preparation of a medicament for treating the acute lung injury. The compound disclosed by the invention can effectively reduce a death rate causedby the acute lung injury and recover the normal lung function, and a treatment effect of the compound is equivalent to that of dexamethasone acetate; and in addition, the compound can be orally taken,is more convenient to use and has important medical prospect and economic value.

The invention discloses an overall-length cDNA sequence for long-chain non-coding RNA, preparation and application. The cDNA sequence of the long-chain non-coding RNA is as shown in SEQ ID NO. 1, the overall-length gene sequence of accurate linc00857 is cloned for the first time, a foundation is laid for research of functions of linc00857 in a generation and development process of adenocarcinoma of lung, high expression of the long-chain non-coding RNA in the adenocarcinoma of lung is obtained by analysis, expression in normal lung tissues is relatively low, expression of the long-chain non-coding RNA is remarkably related to progression of the adenocarcinoma of lung, therefore, the invention further discloses application of the long-chain non-coding RNA in preparation of products for diagnosing or treating the adenocarcinoma of lung, for example, a short hairpin fragment of an RNAi target site of the long-chain non-coding RNA and expression of recombinant plasmids of transcribed short hairpin RNA in cells of the adenocarcinoma of lung can obviously degrade cell endogenous long-chain non-coding RNA and inhibit malignant growth of the cells of the adenocarcinoma of lung.

The invention provides methylation molecular markers for diagnosing lung adenocarcinoma and application of the methylation molecular markers for diagnosing lung adenocarcinoma. The methylation molecular markers are methylated EID3 genes, and by measuring expression of EID3 genes and the methylation levels in samples, lung adenocarcinoma is diagnosed. According to the methylation molecular markersfor diagnosing lung adenocarcinoma and application of the methylation molecular markers for diagnosing lung adenocarcinoma, the fact that the methylated EID3 genes can be used as diagnosis markers oflung adenocarcinoma is proven for the first time due to the fact that the EID3 are significantly hypermethylated in lung adenocarcinoma tissue relative to the EID3 in paracancerous normal lung tissue;and specific high expression of the methylated EID3 genes in the lung adenocarcinoma tissue provides a novel path for diagnosis of lung adenocarcinoma. A kit used for detecting the methylated EID3 genes is provided. The kit used for detecting the methylated EID3 genes is high in detection accuracy, so that a faster and more accurate detection method is provided for diagnosis of lung adenocarcinoma.

The invention relates to identification and application of lncRNA (long non-coding RNA) XLOC_000090 in lung cancer. A nucleotide sequence of an lncRNA XLOC_000090 expression gene is represented as SEQ ID No.1. An interrelation of XLOC_000090 expression and invasion, metastasis and prognosis of NSCLC (non-small cell lung cancer) is studied; differentially expressed lncRNA of 10 pairs of lung cancer tissue and normal lung tissue corresponding to the lung cancer tissue is screened out with a gene chip technology, and a result indicates that the expression of XLOC_000090 in the lung cancer is remarkably higher than that in the normal lung tissue. Therefore, the disclosed lncRNA XLOC_000090 expression gene can be used for detecting whether the lung cancer cells metastasize.

The invention relates to the technical field of biomedicine engineering and provides application of a reagent for inhibiting or down-regulating expression of a GTSE1 gene in preparation of a tumor radiotherapy sensitization drug, particularly application in preparation of a lung cancer radiotherapy sensitization drug. Experiments prove that GTSE1 knockdown promotes DNA damage of exposure to lung cancer cells, increases the radiosensitivity of three lung censer cells significantly and increases the apoptosis rate of the three lung cancer cells after exposure significantly with the increase of an exposure dose, and the cell survival rate of the three lung cancer cells is obviously lower than that of a normal lung cancer cell group. Therefore, the application provides a new exploration for improving the sensitivity of radiotherapy, contributes to radiotherapy sensitivity of malignant tumor and has certain clinical application prospects.

The invention relates to the field of lung cancer treatment, in particular to genetic biomarkers for predicting or assisting in predicting the risk of radiation pneumonitis after pulmonary radiation,and application of the genetic biomarkers. The genetic biomarkers comprise single-nucleotide polymorphic sites from RP2-01 to RP2-31; and the group of the genetic biomarkers fills in the absence of abiomarker which can be used for predicting the risk of radiation pneumonitis after the pulmonary radiation in patients in the prior art. The group of the single-nucleotide polymorphic sites is of different genotypes in different individuals; the different genotypes can affect the sensitivity of normal lung tissues to radiation; by detecting and evaluating the sites, a prognosis can be assisted; and the genetic biomarkers are of great significance to guide the monitoring and treatment of patients with a lung cancer after radiotherapy.

The invention provides an inhibitor gRNA for targeted therapy of lung cancer, application of the inhibitor as well as application of a KAP1 encoding gene as drug target in screening of anti-lung cancer drugs, belonging to the technical field of biological medicines. The inhibitor gRNA for the targeted therapy of the lung cancer can effectively inhibit the expression of the KAP1 encoding gene, thusremarkably inhibiting cell proliferation. The invention also discloses the application of the KAP1 encoding gene as the drug target in screening of the anti-lung cancer drugs. By detecting the expression level of KAP1 in clinical lung cancer tissues and adjacent normal lung tissues, the expression level of the KAP1 in the clinical lung cancer tissues is proved to be obviously higher than that inthe adjacent normal lung tissues. By inhibiting the expression level of the KAP1, the cell proliferation and cell migration are effectively inhibited, a theoretical basis is provided for clinical treatment of the lung cancer, and the new drug target is screened for application.

The invention discloses a standardized culture medium and a culture method for three-dimensional culture of lung and lung cancer tissue organoids. The standardized culture medium comprises at least one or more of a reagent A and a reagent B, wherein the reagent A comprises one or more of R-spondin1, Noggin, N-acetylcysteine, nicotinamide, Y-27632, A8301, SB202190, FGF-7 and FGF-10; the reagent B comprises a reagent B1, a reagent B2 and a reagent B3; the reagent B1 comprises one or more of bovine pituitary protein extract, Y-27632, DAPT, hydrocortisone, insulin, gentamicin, amphotericin, tretinoin, transferrin, iodomethacin, epinephrine and human epidermal growth factors; the reagent B2 comprises heparin; and the reagent B3 comprises one or more of DMEM / F12, L-ascorboic acid-2-phosphate magnesium and sodium selenium. According to the standardized culture medium and the culture method, aiming at the growth characteristics of adult stem cells in lung tissues, multiple growth factor components are selected for blending, and by optimizing the proportion of growth factors in the culture medium, normal lung tissues and lung cancer cells can effectively form lung and lung cancer organoidsin a three-dimensional culture environment.

The present invention relates to a composition for treating or ameliorating lung cancer comprising a glucocorticoid-based compound, a glucocorticoid-based compound and an mTOR inhibitor, or a glucocorticoid-based compound and an AMPK inhibitor as an active ingredient. The glucocorticoid-based compounds inhibit the growth of cancer cells by suppressing NRF2 in KEAP1 mutant lung cancer or KEAP1 andLKB1 mutant lung cancer, and exhibit a more potent anticancer effect when used in combination with the mTOR inhibitor, and thus the compounds can be effectively used as anticancer agents for mutant lung cancer. In addition, one of the characteristics of tumor microenvironments, a low nutrient environment, induces activation of NRF2 and AMPK in KEAP1 and LKB1 normal lung cancer, and the glucocorticoid-based compounds exhibit a strong anticancer synergistic effect in a low nutritional state when treated in combination with an AMPK inhibitor in KEAP1 and LKB1 normal lung cancer, and thus the compounds can also be used as an anticancer agent for KEAP1 normal lung cancer.

The invention discloses a composition for treating acute lung injury, and application thereof. The composition is prepared from (a) dexamethasone and (b) WX-UK1 or WX-671. The research finds that thecomposition formed by dexamethasone and WX-UK1 or WX-671 is safe in component, can effectively have a synergistic treatment effect on acute lung injury, reduces the death rate caused by acute lung injury, recovers normal lung functions, and has important medical prospects and economic values.

The invention discloses lung adenocarcinoma biomarkers and related application, and the biomarkers are at least two of S100P, COL17A1, CXCL14 and GLB1L3. The study of the present invention demonstrates that the mRNA expression levels of S100P, COL17A1, CXCL14 and GLB1L3 genes are significantly up-regulated in lung adenocarcinoma patients compared with normal lung tissues. ROC curve analysis showsthat the combination of the above genes has a high AUC value, suggesting that S100P, COL17A1, CXCL14 and GLB1L3 can be combined and applied for the diagnosis of lung adenocarcinoma, and can be used toprepare products for the diagnosis of lung adenocarcinoma, and the products can be used in clinical application.

The invention discloses a 1-(2,6-chlorphenyl)-3-substituted urea compound capable of acting on colon cancer, a preparation method and applications thereof. According to the present invention, the 1-(2, 6-dichlorophenyl)-3-(6-(substituted benzylamino)pyrimidine-4-yl) urea compound does not have toxic effect on the proliferation of BEAS-2B cells (normal lung cells), and has a certain inhibitory effect on three selected colon cancer cell lines including SW116 cells (human large intestine cancer cells), SW480 cells (human colon cancer cells) and SW620 cells (human colon cancer cells) so as to provide a certain antitumor activity.

The invention discloses an application of a biological marker to diagnosis of lung adenocarcinoma. The biological marker includes two or three of S100P, EEF1A2 or MUC3A. Particularly, the invention provides an application of a detection reagent of the biological marker to preparation of products for diagnosis of the lung adenocarcinoma and the risk assessment of the occurrence of the lung adenocarcinoma. Experiment proves that compared with normal lung tissue, lung adenocarcinoma tissue has the advantages that the gene expression of the S100P, the EEF1A2 or the MUC3A is significantly increased. The ROC curve analysis shows that the genes are in united application to have higher AUC value. According to the research findings disclosed by the invention, the S100P, the EEF1A2 or the MUC3A canbe in united application to the diagnosis of the lung adenocarcinoma.

The invention provides a one-way valve opening device. The device comprises a gasket and a plurality of elastic fine fibers, wherein one ends of the multiple fine fibers are fixed to the gasket, and the other ends of the fine fibers are free; the pressure of the free ends is not lower than that of the fixed ends, the free tail ends of the multiple fine fibers are kept in a gathering state, and the multiple fine fibers are integrally in a cone shape; and when the pressure of the free ends is lower than that of the fixed ends, the free tail ends of the multiple fine fibers are dispersed and are in an open state. The device is arranged in the indwelling needle, and thrombus generated in the using process of the indwelling needle can be stopped in a needle seat, so that the thrombus is prevented from entering the human body, and the serious consequence caused by the fact that the thrombus enters the human body is reduced. The device is placed in the bronchus of a lesion area of the human body, the movement direction of sputum can be limited, the sputum can be discharged out of the body, the access of gas and liquid is not limited, the air inflow of the lung in the lesion area can be directly reduced, the ventilation / perfusion blood flow proportion of the normal lung can be indirectly improved, and meanwhile the follow-up treatment such as alveolar lavage is not affected.

The invention discloses a lung cancer tissue separator, and the separator comprises a table top, a transverse moving device, a separating device, a clamping device, a portal frame and an opening device; when a lung cancer tissue separation operation is carried out, a patient needs to lie on the table top, then the portal frame moves to the position over the part, needing the operation, of the patient, and then the separating device is driven to move downwards to a proper position; the distraction device is used for distraction of a surgical incision of a patient and guaranteeing a surgical space, the clamping device located over clamps a focus, the separation device rotates by 180 degrees to cut off a membrane on the outer side of a pulmonary lobe, then the clamping device located on the side clamps pulmonary lobe tissue below the incision, the clamping device located above moves upwards, blunt separation of cancer tissue and normal lung tissue is achieved, blood vessels are exposed, separation of the cancer tissue is completed after the blood vessels are sutured, and the device has the advantages of being high in automation degree, convenient to operate, safe and reliable.

The invention belongs to the field of biotechnology, and particularly relates to PLEKHN1 as a new target for prevention and diagnosis of arsenic compound-induced lung cancer and application thereof. Specifically, the invention discloses application of a PLEKHN1 expression inhibitor in the preparation of lung cancer prevention / treatment drugs; and knockdown of PLEKHN1 can significantly inhibit arsenic compound-induced malignant transformation action of normal lung cells.

The present invention provides a detection method based on detecting the autofluorescence level of lung tissue as a detection method for lung cancer tissue, comprising the following steps: (1) detection of lung tissue under single-photon 400-700nm excitation light or two-photon 700-1000nm excitation light Under excitation, the emitted wavelength is autofluorescence of 420-800nm; (2) compare the autofluorescence intensity of various parts of the lung tissue in step (1), and compare the autofluorescence in step (1) with the known lung cancer patient Compared with the autofluorescence intensity results of the non-lung cancer population; (3) The location and size of the lung cancer tissue can be determined according to the above comparison results. The intensity of autofluorescence light emitted by lung tissue with a wavelength of 420-800nm ​​is negatively correlated with the possibility of the tissue being lung cancer tissue: the part with higher autofluorescence intensity is normal lung tissue, while the lower the intensity of autofluorescence light The more likely the part is lung cancer tissue.

The invention discloses a COVID-19 classification and identification method based on lung CT images, and the method comprises the steps: collecting a normal lung CT image, a lung tumor CT image and aCOVID lung CT image, obtaining three sample subsets, and forming a sample set; respectively pre-training three convolutional neural networks, namely AlexNet, GoogleNet and ResNet, by adopting a transfer learning method to respectively obtain initialization parameters of the three convolutional neural networks; respectively inputting the sample set into three pre-trained convolutional neural networks to obtain three individual classifiers; and integrating the three individual classifiers by adopting an ensemble learning method to obtain an ensemble classifier model. The overall classification performance of the integrated model is superior to that of an individual classifier, evaluation indexes such as specificity and sensitivity are high, and the requirement for rapid recognition of COVID-19 lung CT images can be well met.

The invention belongs to the technical field of biomedical testing, and particularly relates to a tRNA related lung adenocarcinoma prognosis model and application of the tRNA related lung adenocarcinoma prognosis model, the tRNA related lung adenocarcinoma prognosis model and the application of the tRNA related lung adenocarcinoma prognosis model comprise providing the application of detecting theexpression level of tRNA in a tissue to the prognosis of the adenocarcinoma of lung, the application is finished through the following steps: step 1, quantifying the tRNA of the adenocarcinoma of lung and the normal lung tissue; step 2, establishing correlation between tRNA and the adenocarcinoma of lung; and step 3, establishing a tRNA related prognosis scoring model. 50 pairs of adenocarcinomaof lung and the corresponding tumor adjacent tissue are screened through a qPCR (Polymerase Chain Reaction) chip, and the quantitative expression condition of the tRNA of the corresponding tissue is disclosed. The invention aims at screening a specific tRNA molecule related to the prognosis of a patient suffering from the adenocarcinoma of lung, and provides the tRNA prognosis model for diagnosingand treating the adenocarcinoma of lung; another purpose of the invention is to provide the application of the specific tRNA combination to the preparation of a kit for predicating the prognosis of the adenocarcinoma of lung, and the invention provides the application of the prognosis model to the prognosis of the adenocarcinoma of lung and a related kit to the diagnosis and the prognosis of theadenocarcinoma of lung.